RIPK1 PROTAC for cancer

A proteolytic targeting chimera (PROTAC) that degrades the serine/threonine kinase RIPK1 could help treat cancer by eliminating RIPK1’s pro-survival, non-catalytic scaffolding functions, resulting in immunogenic cell death.

In an analysis of data from The Cancer Genome Atlas, high RIPK1 copy number was associated with poor survival. ...